Its therapeutic relevance in lipedema derives from the shared pathophysiological mechanisms among these conditions, particularly in the context of progesterone resistance, aromatase overexpression, and enzymatic imbalance—marked by increased 17β-HSD1 and reduced 17β-HSD2. The gene discussed is CYP19A1; the disease is Lipedema.